Stuart Therapeutics

    Company Information

    Stuart Therapeutics is based in Stuart, Florida, USA. The number of employees in Stuart Therapeutics is unknown. Stuart therapeutics is a biotechnology company that offers polycol, a therapeutic platform for ophthalmic indications.
      If you are the founder or part of the founding team, please tell the world your story


          Funding & investors

          Stuart Therapeutics has received 2 rounds of venture funding. The total funding amount is around $22M. Last venture funding round was $11M, announced on March, 2021.

            Similar Companies [beta]

              Venture Categories

                Active Venture Investors




                  Venture Competitors

                    News

                        Stuart Therapeutics - Blog

                          • Stuart Therapeutics, Inc. Announces Completion of Patient Enrollment in Phase 2 Clinical Trial for Dry Eye Disease

                          • Stuart Therapeutics, Inc. Announces Completion of Patient Enrollment in Phase 2 Clinical Trial for Dry Eye Disease STUART, Fla., Sept. 8, 2021 /PRNewswire/ — Stuart Therapeutics, Inc. (“Stuart“), a clinical stage biopharmaceutical company conducting research and development of unique peptide therapeutics for ophthalmic diseases, today announced that it has completed patient enrollment in its Phase 2...
                          • Stuart Therapeutics Completes its $11M Series A Round, led by InFocus Capital Partners, WARF and MiMo Capital

                          • Stuart Therapeutics Completes its $11M Series A Round, led by InFocus Capital Partners, WARF and MiMo Capital Stuart Therapeutics, Inc. (“Stuart”), a clinical stage biopharmaceutical company conducting research and development of unique peptide therapeutics for ophthalmic diseases, today announced the completion of an $11 million Series A round of capital investment. The round was led...
                          • Stuart Therapeutics Announces Receipt of Study May Proceed Letter from U.S. FDA for ST-100 Dry Eye Disease Phase 2 Clinical Trial

                          • Stuart Therapeutics Announces Receipt of Study May Proceed Letter from U.S. FDA for ST-100 Dry Eye Disease Phase 2 Clinical Trial Stuart Therapeutics (Stuart) announced today that the U.S. Food and Drug Administration (FDA) has completed its review of an Investigational New Drug (IND) application for Stuart’s investigational product ST-100, a topical drop formulation designed...
                          • Stuart Therapeutics Wins the AdvanSE Life Sciences Conference PitchRounds Competition

                          • Stuart Therapeutics Wins the AdvanSE Life Sciences Conference PitchRounds Competition November 13th, 2020, Stuart, Florida For Immediate Release Stuart Therapeutics, Inc. (Stuart), a pre-clinical stage company developing advanced ophthalmic therapeutics, announced today that the company’s presentation at the Southeast Life Sciences AdvanSE Life Sciences Conference was judged the winner of the PitchRounds Competition. The competition...
                          • Stuart Therapeutics, Inc. Announces Presentation at ARVO 2020

                          • Stuart Therapeutics, Inc. Announces Presentation at ARVO 2020 Stuart Therapeutics, Inc. (STUART), the leader in the application of collagen mimetic peptide (CMP) technology for ophthalmology, today announced that it has been selected as a presenter at the Association for Research of Vision and Ophthalmology (ARVO) 2020 Annual Meeting in Baltimore, Maryland, May 3rd through 7th...
                          • Stuart Therapeutics, Inc. Announces Pro-Neuronal Growth Results Using PolyColTM Collagen Mimetic Peptides

                          • STUART, FLORIDA November 11th, 2019: Stuart Therapeutics, Inc. (STUART), an innovative pre-clinical therapeutic development company, today announced that it has successfully completed in vitro pro-neuronal growth experiments utilizing the company’s PolyColTM (PolyCol) peptide. PolyCol demonstrated a strong propensity to encourage neurite outgrowth from dorsal root ganglia nerve cells in a model designed to mirror damage...

                          Share:     facebook    twitter    linkedin    reddit    email

                            Ventures Media is one of the largest startup and venture capital communities for startup and venture capital funding information and analysis.

                            Leave a Reply

                            Your email address will not be published. Required fields are marked *